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http://dx.doi.org/10.1016/j.celrep.2014.05.005Mitochondrial DNA (mtDNA) mutations, a
major cause of maternally inherited hu-
man diseases, are commonly character-
ized by the coexistence of mutant and
wild-type mtDNA molecules within a cell
(called ‘‘heteroplasmy’’ or ‘‘mutation
load’’). Usually, the higher the mutation
load, the more severe the disease.
Because of the high risk of recurrence in
siblings and the absence of treatment op-
tions, couples at risk of transmitting
mtDNA mutations often ask for prenatal
diagnosis (PND) or preimplantation ge-
netic diagnosis (PGD). These procedures
are based on assessment of the mutation
load (percentage of mutant mtDNA / total
mtDNA) in either tissues (PND) or cells
(blastomeres in a day 3 embryo). The pre-
dictive value of these procedures for post-
natal outcome assumes that the mutation
load is relatively stable among blasto-
meres at the 8-cell-stage embryo or in tis-
sues throughout the entire embryofetal
development.
By measuring mtDNA heteroplasmy
levels in single blastomeres sampled
from 8-cell-stage macaque embryos,
Lee et al. reported a significant difference
in heteroplasmy levels among cells from a
given embryo, questioning the reliability of
the PGD procedure in clinical practice
(Lee et al., 2012). In their experiments,
they removed half the cytoplasm of an
oocyte derived from a female rhesus ma-
caque and fused it with another halved
oocyte containing the spindle-chromo-
somal complex recovered from a second
female, thus generating artificially hetero-Cell Rplasmic embryos containing 50% of each
mtDNA species. They observed a large
variation of mtDNAmutation loads among
blastomeres (mean of the standard devia-
tions [SDs] of 15%, ranging from 3% to
28%). This feature increased dramatically
during the first cleavages, and it was still
present at the blastocyst stage. On the
basis of these observations, Lee et al.
concluded that heteroplasmy in one bio-
psied blastomere from cleaving embryos
may not be predictive of total mutation
load in the remaining blastomeres and
the whole embryo. They therefore sug-
gested that chorionic villus sampling
could be more reliable than blastomere
assessment for the prediction of embry-
onic mutation load.
Our experience of PGD for mtDNA
mutations in humans does not support
conclusions from these macaque experi-
ments. Indeed, all studies on human het-
eroplasmic embryos hitherto conceived
by in vitro fertilization have shown quite
good stability of the mutation load among
blastomeres, irrespective of the variant
type: a mtDNA polymorphism (HV2 tract,
Steffann et al., 2006) or mtDNA mutations
(m.3243A>G, m.8993T>G, m.8344A>G,
m.9185T>C, m.10197G>A, Steffann
et al., 2006, Monnot et al., 2011, Treff
et al., 2012, Vandewoestyne et al., 2012,
Sallevelt et al., 2013). Figure S1C summa-
rizes all published data and unreported
personal observations regarding single-
blastomere analysis on a total of 105
human embryos carrying various mtDNA
mutations. At variance with the SDeports 7, 933–934, May 22, 2014 ª2014 The Auobserved by Lee et al. (15%), the mean
SD of the mutation loads was very low in
our series (less than 2%), which can be
ascribed to reproducibility of the tech-
nique (Steffann et al., 2006). In the less
favorable cases, the SD was consistently
below 15%, far less than the SD figure re-
ported by Lee et al. (28%). For compari-
son between data from the macaque
experiment and human clinical data, we
plotted the rate of mutation in one
randomly chosen blastomere (using a
random number generator) against that
in remaining cells of the same embryo
(Figure S1). In rhesus macaque embryos,
the test blastomere heteroplasmy was
poorly predictive of the heteroplasmy
observed in the remaining seven
blastomeres (R2 = 0.066, Figure S1A).
Conversely, in human embryos, the test
blastomere heteroplasmy was highly pre-
dictive of the mutation load in the remain-
ing blastomeres (R2 = 0.98, Figure S1B).
The linear regression wasmore significant
in human than in rhesus macaque
embryos (p < 0.0001 and p = 0.0013,
respectively).
Why results differ so markedly across
species is an interesting question, espe-
cially given that mouse heteroplasmic
embryos were reported to display very
little variations in heteroplasmy levels
among blastomeres (mean 2%, ranging
from 0 to 6%, Dean et al., 2003). The dif-
ference may be due to the experimental
procedure used to generate the hetero-
plasmic macaque model, which is likely
to result in an mtDNA segregation pattern933thors Open access under CC BY-NC-ND license.
different from that occurring in nonmani-
pulated embryos. Because such embryos
are formed by the merging of two distinct
cytoplasts, mitochondria fromdonors and
acceptors may be clustered in different
cell areas, leading to a nonrandom distri-
bution of mtDNA populations between
the two daughter cells. Such a hypothesis
is supported by the results of another
study, carried out in the mouse, using a
microsurgery approach similar to that of
Lee et al. in the monkey (Meirelles and
Smith, 1998). The variation of hetero-
plasmy among blastomeres was 10-fold
higher in reconstructed embryos than in
zygotes derived from heteroplasmic line-
age (Meirelles and Smith, 1998). In their
cases, the supposed ‘‘rapidmitochondrial
DNA segregation’’ was ascribed to a par-
titioning of mtDNA genotypes occurring in
the process of fusing the two egg cells, a
feature that probably does not occur in
naturally heteroplasmic oocytes.
These observations emphasize the
risk of mis-segregation of mtDNA mole-
cules in ‘‘artificially generated embryos.’’
Lee’s artificial model of mtDNA disorders
might thus be more relevant to prevent-
ing the transmission of mtDNA disorders
by nuclear transfer than by embryonic
selection using PGD. However, it has to
be emphasized that small amounts of
mutant mtDNA are usually cotransferred
with the karyoplast during nuclear trans-
fer from affected to donor oocyte (Tachi-
bana et al., 2009, Craven et al., 2010).
Even if rapid segregation of mutant
mtDNA occurs, the risk induced by the
resulting heteroplasmy can probably be
regarded as negligible. Technical im-
provements have indeed decreased the
carryover heteroplasmy to levels below934 Cell Reports 7, 933–934, May 22, 2014 ª1%, far less than the threshold of mtDNA
disease.
Taken together, our data, as well as
those from other groups, advocate a ho-
mogeneous distribution of wild-type and
mutant mtDNAs in individual human blas-
tomeres at the 8-cell stage, regardless of
the mutation. They support the reliability
of PGD procedures based on mutation
load assessment on two different blasto-
meres sampled at day 3 (Monnot et al.,
2011, Sallevelt et al., 2013, Vandewoes-
tyne et al., 2012). Moreover, stability of
the mutation loads between the inner cell
mass and the trophectoderm has been re-
ported at the blastocyst stage (Treff et al.,
2012), at least for the m.3243A>G muta-
tion, supporting the feasibility of PGD on
a day 5 trophectoderm biopsy. The four
children born to date after a PGD proce-
dure had buccal cell or cord blood muta-
tion loads very similar to the blastomere
mutation loads (m.8993T>G: 0% versus
0% in the embryos [Steffann et al., 2006],
m.3243A>G: 15% versus 12% [Treff
et al., 2012] and 5% versus 5% and 13%
[two transferred embryos; Monnot et al.,
2011], m.8344A>G: 63% versus 53%
and 59% [two transferred embryos; this
report]). Although more data are certainly
needed in order to document the stability
of the mutation loads throughout human
in utero development, these observations
support the reliability of standard PGD
procedures on human embryos at risk of
carrying mtDNA mutations.SUPPLEMENTAL INFORMATION
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